Eli Lilly Lawsuit 2026: Claims, Payouts & Who Qualifies

Quick Answer

• Eli Lilly faces multiple active lawsuits in 2026, covering insulin price-fixing, Mounjaro and Zepbound injury claims, and legacy Zyprexa litigation across two major federal MDLs.
• Qualifying plaintiffs include consumers who paid inflated insulin prices, patients who developed gastroparesis or other serious GI injuries after taking GLP-1 drugs, and in some tracks, former Zyprexa users with documented harm.
• Estimated payouts range from $25,000 to $150,000+ per claimant depending on severity of injury, with the insulin antitrust track structured as a class-wide damages fund.

Case Snapshot

Eli Lilly and Company is fighting litigation on multiple fronts in 2026, with two major federal multidistrict proceedings and a growing inventory of individual state-court filings. The company's exposure spans at least three distinct legal theories: antitrust price-fixing on insulin, product liability for GLP-1 drug injuries, and residual claims from the Zyprexa off-label marketing era.

Combined potential liability across all active tracks runs into the billions. The insulin pricing MDL alone involves class representatives from nearly every U.S. state. The GLP-1 mass tort is expanding faster than any pharmaceutical litigation since the opioid MDL at its peak.

Before you go further, consider reading Drake UMG Lawsuit 2026: Claims, Court Status, Outcome

Readers who used Mounjaro, Zepbound, Trulicity, Humalog, or Basaglar, or who paid full retail for insulin between 2009 and the present, may have a viable claim in one or more of these proceedings. The legal picture in 2026 is still moving, and understanding the specific track that applies matters before contacting an attorney.

Eli Lilly Lawsuit 2026: Where the Litigation Stands Now

Eli Lilly's litigation exposure in 2026 is broader and more procedurally advanced than at any prior point in the company's history. Two federal MDLs are simultaneously active, and state-level enforcement actions have added a parallel layer of pressure.

MDL No. 2724 in the District of New Jersey entered its ninth year of litigation in 2026. Settlement negotiations have intensified following the court's class certification rulings. The GLP-1 MDL (No. 3094 in the Eastern District of Pennsylvania) moved into the bellwether selection phase in late 2025, with trial dates projected for mid-2026 through 2027.

Eli Lilly reported that its legal reserve for unresolved litigation reached approximately $1.2 billion as of its most recent quarterly filing. That figure does not represent a settlement fund; it is an internal accounting estimate for potential exposure.

Key 2026 Status Points:

• Insulin MDL: Class certification granted for consumer subclass; damages phase ongoing
• GLP-1 MDL: Bellwether trials scheduled; discovery mostly complete
• Zyprexa: No new class filings; individual legacy claims in scattered state courts
• State AGs: At least 8 states pursuing independent enforcement actions on insulin pricing

*Attorneys handling these claims point to the bellwether trial schedule in MDL 3094 as the most consequential near-term development, since those early verdicts will anchor settlement negotiations for thousands of pending GLP-1 cases.*

Eli Lilly Class Action: How These Cases Are Structured

The Eli Lilly class action in the insulin pricing track is structured as a consolidated antitrust class action, not a mass tort. That distinction matters for how plaintiffs recover.

In the antitrust class, class representatives sue on behalf of all consumers who paid above-market prices for insulin products, including Humalog and Basaglar, during the class period. Individual plaintiffs do not need to prove personal injury. They need to show they paid the inflated price.

The GLP-1 litigation is structured differently. It is a mass tort, not a class action. Each plaintiff files an individual complaint, which is then consolidated into MDL No. 3094 for pretrial proceedings. Damages are individualized, not shared across a fund.

Structure Comparison:

*Attorneys handling these claims point to the opt-out mechanism in the antitrust class as a strategic decision: plaintiffs with evidence of significant individual damages may recover more by opting out and filing separately.*

Eli Lilly Insulin Pricing Lawsuit: The Antitrust Case Explained

The Eli Lilly insulin pricing lawsuit is built on an antitrust theory alleging that Eli Lilly, Novo Nordisk, and Sanofi coordinated with pharmacy benefit managers to artificially inflate the list prices of insulin while negotiating secret rebates. The result, plaintiffs allege, was that uninsured and underinsured patients paid catastrophically inflated out-of-pocket costs.

MDL No. 2724 before Judge Martinotti in Newark has been the central vehicle for this litigation since 2017. The list price of Humalog rose from approximately $21 per vial in 1999 to over $274 per vial by 2017, a 1,200% increase that plaintiffs argue far exceeded any cost-of-production justification.

Eli Lilly voluntarily capped its out-of-pocket insulin costs at $35 per month in March 2023 for patients using its products. Plaintiff attorneys have argued that cap does not resolve the prior decade-plus of overcharges, and the MDL continues on damages for that historical period.

Alleged Co-Conspirators in MDL 2724:

• Eli Lilly and Company (Humalog, Basaglar)
• Novo Nordisk (Novolog, Levemir)
• Sanofi (Lantus, Toujeo)
• CVS Caremark (PBM)
• Express Scripts (PBM)
• OptumRx (PBM)

*Attorneys handling these claims point to the parallel FTC investigation into PBM rebate practices as corroborating evidence that may strengthen the damages case in MDL 2724.*

Litigation Watch: The insulin antitrust MDL, the GLP-1 mass tort, and the Zyprexa legacy track are three legally distinct proceedings with separate courts, separate theories, and separate eligibility standards. Treating them as a single "Eli Lilly lawsuit" leads to incorrect eligibility assessments.

Eli Lilly Mounjaro Lawsuit: What Plaintiffs Are Alleging

The Eli Lilly Mounjaro lawsuit centers on claims that the company failed to adequately warn patients and physicians about the risk of serious gastrointestinal injuries, specifically gastroparesis, severe vomiting, intestinal obstruction, and ileus.

Mounjaro received FDA approval in May 2022 for type 2 diabetes management. Zepbound, the same tirzepatide molecule reformulated for obesity, received approval in November 2023. Both products are named in individual complaints consolidated under MDL No. 3094.

Plaintiffs allege they were hospitalized with severe GI complications that the FDA-approved labeling, as it existed at the time of their use, did not sufficiently disclose. The FDA required updated gastroparesis warnings on GLP-1 class drugs in late 2023, which plaintiffs argue confirms the hazard was known and underreported.

Commonly Alleged Injuries in Mounjaro Claims:

• Gastroparesis (stomach paralysis)
• Cyclic vomiting syndrome
• Intestinal obstruction or ileus
• Aspiration pneumonia from delayed gastric emptying
• Severe dehydration requiring hospitalization

*Attorneys handling these claims point to the 2023 FDA label update as a critical timeline marker: plaintiffs who experienced injuries before that update have stronger "failure to warn" arguments because the hazard disclosure was materially inadequate at the time of their use.*

Eli Lilly Zyprexa Lawsuit: Legacy Settlements and Remaining Claims

The Eli Lilly Zyprexa lawsuit represents one of the most significant pharmaceutical settlements in U.S. history, though that litigation is largely resolved. Between 2005 and 2009, Eli Lilly paid approximately $1.415 billion in a federal criminal fine and settled thousands of civil claims related to off-label marketing of the antipsychotic Zyprexa (olanzapine).

The company was found to have promoted Zyprexa for unapproved uses, including dementia in elderly patients, without adequate evidence of efficacy for those indications. It also concealed data on metabolic side effects, including significant weight gain and diabetes risk.

In 2026, no active class action against Eli Lilly for Zyprexa remains viable. The statute of limitations has run for most potential plaintiffs. However, a small number of individual claimants with extraordinary circumstances, including plaintiffs who were minors during the relevant period, may still have active state-court actions depending on the tolling rules of their jurisdiction.

Zyprexa Settlement History:

*Attorneys handling these claims point to Zyprexa as a precedent case: Eli Lilly's prior pattern of concealing adverse metabolic data informs how plaintiff firms approach discovery in the current GLP-1 litigation.*

Eli Lilly GLP-1 Lawsuit: Gastroparesis and Serious Side Effects

The Eli Lilly GLP-1 lawsuit, formally consolidated as MDL No. 3094 in the Eastern District of Pennsylvania before Judge Karen Marston, is the fastest-growing pharmaceutical mass tort in the country as of 2026. It encompasses claims against Eli Lilly's tirzepatide products (Mounjaro and Zepbound) alongside parallel claims against Novo Nordisk's semaglutide products (Ozempic and Wegovy).

The central allegation is product liability: specifically, failure to warn. Plaintiffs do not argue the drugs do not work. Many plaintiffs achieved significant weight loss or blood sugar control. The argument is that the severity of GI side effects, particularly gastroparesis, was known to manufacturers based on their own clinical trial data and was not disclosed with adequate specificity.

GLP-1 MDL 3094 at a Glance:

*Attorneys handling these claims point to the bellwether trial results as the hinge point for global settlement negotiations: a plaintiff verdict in the $5 million to $15 million range would accelerate settlement talks for the broader docket.*

Litigation Watch: The GLP-1 MDL is the most consequential active litigation track for most current Eli Lilly plaintiffs. The bellwether trial outcomes in 2026 will determine whether global settlement negotiations begin in earnest or whether Eli Lilly contests individual cases through jury trial.

Eli Lilly Trulicity Lawsuit: Separate Track or Same MDL?

Trulicity (dulaglutide) is an older GLP-1 receptor agonist that Eli Lilly marketed primarily for type 2 diabetes management before Mounjaro entered the market. In 2026, Trulicity claims are consolidated within MDL No. 3094 alongside Mounjaro and Zepbound claims. They are not a separate MDL.

The mechanism of injury alleged for Trulicity is identical to that alleged for tirzepatide drugs: GLP-1 receptor agonism slows gastric emptying, and in a subset of patients, that slowing becomes pathological. Plaintiffs who developed gastroparesis while taking Trulicity before switching to Mounjaro, or who took only Trulicity, file under the same MDL structure.

Trulicity's U.S. patent exclusivity has expired, and the drug faces biosimilar competition. That commercial shift has reduced Eli Lilly's financial incentive to defend Trulicity claims as aggressively as its newer tirzepatide franchise.

Trulicity vs. Mounjaro in MDL 3094:

*Attorneys handling these claims point out that Trulicity plaintiffs with documented gastroparesis diagnoses predate the FDA's 2023 label update, which may strengthen their failure-to-warn argument given the longer period of inadequate warning.*

Eli Lilly Antitrust Lawsuit: The Price-Fixing Theory Unpacked

The Eli Lilly antitrust lawsuit rests on a specific legal theory under the Sherman Act and state consumer protection statutes: that coordinated conduct between insulin manufacturers and pharmacy benefit managers constituted a per se restraint of trade. This is not a products liability case. It is a price-fixing case.

The mechanism alleged is what plaintiff economists call a "rebate trap." Insulin makers set artificially high list prices. They then pay PBMs enormous rebates, a percentage of that inflated list price, in exchange for favorable formulary placement. The higher the list price, the larger the rebate. Uninsured patients who pay list price bear the full cost of that artificial inflation.

The Alleged Rebate Trap Mechanism:

1. Eli Lilly sets Humalog list price at $274/vial
2. Eli Lilly pays CVS Caremark a rebate of approximately 70-80% of list price
3. CVS places Humalog favorably on formulary; patients with insurance pay low copays
4. Uninsured patients pay the full $274 list price
5. Eli Lilly and PBM split the inflated margin; the uninsured patient absorbs the cost

The DOJ Antitrust Division has previously investigated aspects of this structure. The FTC issued a report in 2022 raising similar concerns about PBM rebate practices as a systemic distortion of pharmaceutical pricing.

*Attorneys handling these claims point to the economic expert testimony filed in MDL 2724 as critical: plaintiff economists have modeled the "but-for" market price of insulin at approximately $48 to $72 per vial absent the alleged coordination, compared to actual prices exceeding $270.*

On a related note, check out Aspen Dental Lawsuit 2026: Claims, Payouts & Class Action

Eli Lilly MDL: Courts, Judges, and Docket Numbers

Two federal MDLs are the primary vehicles for active Eli Lilly litigation in 2026. Understanding which court handles which claims prevents misfiled complaints and missed deadlines.

MDL No. 2724 is captioned "In Re: Insulin Pricing Litigation" and sits in the U.S. District Court for the District of New Jersey, Newark vicinage. Judge Brian R. Martinotti has presided since consolidation. The lead consumer plaintiff case was filed in April 2017.

MDL No. 3094 is captioned "In Re: Ozempic (Semaglutide) and Wegovy Products Liability and Personal Injury Litigation" and sits in the U.S. District Court for the Eastern District of Pennsylvania, Philadelphia. The caption reflects the early filing mix; Eli Lilly's tirzepatide claims are fully consolidated within this MDL. Judge Karen Marston was assigned in 2023.

MDL Court Reference Table:

*Attorneys handling these claims point to the importance of proper short-form complaint filings in MDL 3094: cases must be filed in the Eastern District of Pennsylvania with a specific GLP-1 direct-file notice, or they risk being remanded to the wrong district.*

Litigation Watch: Eli Lilly faces two simultaneous federal MDLs with two different judges in two different courts, each on different legal theories. A plaintiff eligible in one MDL may have no standing in the other. Identifying the correct MDL at the outset determines everything that follows in terms of discovery, trial preparation, and eventual settlement structure.

Eli Lilly Lawsuit Who Qualifies: The Core Eligibility Questions

Eligibility for an Eli Lilly lawsuit depends entirely on which litigation track the plaintiff's facts fit. There is no universal qualification standard across all three active tracks.

For the insulin antitrust class action (MDL 2724), the core question is whether the plaintiff paid out-of-pocket for Eli Lilly insulin products during the class period at prices above what they would have paid in a competitive market. Insured patients who paid a flat copay generally do not qualify as consumer class members; their insurer absorbed the overcharge.

For the GLP-1 mass tort (MDL 3094), eligibility turns on two factors: documented use of a qualifying GLP-1 drug (Mounjaro, Zepbound, or Trulicity from Eli Lilly; Ozempic or Wegovy from Novo Nordisk) and a diagnosed qualifying injury, primarily gastroparesis, intestinal obstruction, or a related serious GI condition.

Core Eligibility by Track:

*Attorneys handling these claims point to medical records as the threshold requirement in the GLP-1 track: a gastroparesis diagnosis must appear in a physician's documented record, not merely a self-reported symptom history.*

Eli Lilly Lawsuit Eligibility: Product-by-Product Breakdown

A product-by-product eligibility analysis helps identify which patients have the strongest standing in which proceeding. The legal strength of a claim tracks directly to documented injury severity and the prescribing timeline relative to label changes.

Mounjaro and Zepbound plaintiffs with gastroparesis diagnoses that predate November 2023, when the FDA required updated GI warning language, present the strongest failure-to-warn claims. That label change is the dividing line between pre-notice and post-notice injury periods.

Trulicity plaintiffs have the advantage of a longer historical window. Trulicity was approved in 2014. Patients who developed severe GI injuries from 2014 through 2022, before any enhanced warning was in place, may have particularly well-supported claims.

Product Eligibility Quick Reference:

*Attorneys handling these claims point to the prescription record as the foundational document: if a plaintiff cannot produce pharmacy records showing the specific drug, dosage, and prescribing period, the claim faces significant obstacles at the summary judgment stage.*

Eli Lilly Lawsuit Settlement Amount: What the Numbers Show

No global settlement has been announced in either MDL 2724 or MDL 3094 as of early 2026. The figures in circulation are projections derived from comparable pharmaceutical mass torts, internal reserve disclosures, and economic expert reports filed in court.

For the GLP-1 mass tort track, with approximately 10,000 claims filed as of January 2026, plaintiff attorneys and legal analysts have modeled potential per-claimant recoveries based on injury severity tiers. Those projections are not guaranteed; they represent settlement ranges from analogous mass torts.

For the insulin antitrust class, the class damages model filed by plaintiff economists estimates aggregate overcharges exceeding $6.5 billion for the consumer subclass across the class period. A global settlement would represent a fraction of that figure, distributed pro-rata.

Projected Settlement Ranges (GLP-1 Mass Tort):

*Attorneys handling these claims point to the first bellwether trial verdict as the number that will actually anchor settlement negotiations: a high plaintiff verdict will push all tiers upward; a defense verdict will compress them.*

Eli Lilly Lawsuit Payout: How Damages Are Calculated

Damages in the GLP-1 mass tort are calculated individually, not as a class-wide fund. Each plaintiff's recovery depends on a combination of economic and non-economic factors that plaintiff attorneys document during the client intake and discovery process.

Economic damages include quantifiable losses: medical bills for hospitalization, diagnostic testing, specialist care, and any surgical interventions; lost wages during recovery; and future medical costs if the injury is permanent. Non-economic damages address pain and suffering, loss of consortium, and diminished quality of life. In cases involving egregious corporate conduct, punitive damages remain possible, though courts impose constitutional limits.

The formula used in comparable mass torts allocates points to plaintiffs based on documented injury severity, duration of drug use, and speed of diagnosis relative to initial drug exposure. Point totals determine each claimant's share of a settlement fund.

Damages Calculation Factors:

• Medical bills and future medical costs (economic)
• Lost wages, present and projected (economic)
• Duration and severity of symptoms (non-economic)
• Documented hospitalization and surgical history (multiplier factor)
• Permanence of gastroparesis or GI injury (tier placement)
• Plaintiff's age and pre-existing conditions (mitigation analysis)
• Prescribing physician's documentation of informed consent

*Attorneys handling these claims point to the hospital admission record as the single most valuable piece of evidence: a plaintiff who was admitted for intractable vomiting or gastroparesis within six months of starting a GLP-1 drug presents a causation timeline that is difficult for the defense to rebut.*

Litigation Watch: The per-claimant recovery in a mass tort is not a lottery; it is a function of documented harm severity, medical records quality, and the overall trajectory of bellwether trial results. Plaintiffs with thorough medical records and clear timelines consistently recover more than those whose documentation is incomplete.

How to File Eli Lilly Lawsuit: Steps and Deadlines

Filing a claim in either active Eli Lilly MDL requires retaining a plaintiff's attorney experienced in pharmaceutical mass torts. Individuals cannot file pro se effectively in an MDL proceeding.

The process for a GLP-1 injury claim in MDL No. 3094 follows a standard mass tort intake sequence. The attorney collects medical records, prescription records, and employment history, drafts and files a short-form complaint in the Eastern District of Pennsylvania, and the case is administratively tagged to the MDL docket. Discovery proceeds under the MDL's master scheduling order.

Filing Process for GLP-1 Claim (MDL 3094):

Statute of Limitations Warning:

Most product liability claims carry a 2-year statute of limitations from the date of injury discovery, though this varies by state. In some jurisdictions, the discovery rule tolls the limitations period until the plaintiff reasonably knew or should have known that the drug caused the injury. Waiting past the applicable deadline extinguishes the claim entirely.

Helpful next step: Mounjaro Lawsuit 2026: Claims, MDL & Settlement

*Attorneys handling these claims point to the "discovery rule" analysis as the threshold issue for any plaintiff who delayed seeking legal counsel: the clock typically starts when the plaintiff received a gastroparesis diagnosis, not when they first felt sick.*

Eli Lilly Lawsuit States: Where Cases Are Being Filed

Eli Lilly lawsuit claims are being filed across all 50 states, but the federal MDL structure means that individual state-court filings are generally removed to federal court and consolidated into the relevant MDL. However, certain state courts remain relevant for specific claim types.

Eight state attorneys general had active or pending enforcement actions related to insulin pricing as of early 2026. California, New York, Minnesota, Washington, Colorado, Connecticut, Michigan, and Oregon have each pursued state-law consumer protection or antitrust theories either independently or in coordination with the federal MDL.

State court remains the primary venue for certain Zyprexa legacy claims where the plaintiff qualifies under a specific state's tolling statute. States with longer statutes of limitations for personal injury or fraud, such as California (3 years with discovery rule) and New York (3 years), may still provide a viable forum for limited Zyprexa claims.

State AG Actions on Insulin Pricing (Active as of 2026):

*Attorneys handling these claims point to California and New York as states where the state AG actions may produce parallel recoveries for consumers, separate from their participation in MDL 2724, potentially increasing total recovery.*

Eli Lilly Settlement: Status, Timelines, and What Comes Next

No comprehensive Eli Lilly settlement has been finalized in either active MDL as of early 2026. This is consistent with the procedural posture of both proceedings, neither has yet produced a bellwether trial verdict that would establish the damages anchor for global settlement talks.

In the insulin pricing MDL (No. 2724), Judge Martinotti has encouraged mediation. Several confidential mediation sessions were reported in the second half of 2025. Settlement discussions are ongoing, but no agreement has been announced publicly, and no claims filing deadline has been court-ordered.

In the GLP-1 MDL (No. 3094), the bellwether trial process is the precursor to settlement. Courts do not approve global mass tort settlements until at least a few individual trials establish what juries will award. That trial data does not yet exist.

Projected Settlement Timeline (Both MDLs):

*Attorneys handling these claims point to the absence of a court-ordered filing deadline as a misleading source of false comfort: the statute of limitations runs independently of the MDL's administrative schedule, and plaintiffs who miss their state-specific deadline lose their claim regardless of where the MDL stands.*

Frequently Asked Questions

What is the Eli Lilly lawsuit about in 2026?

The Eli Lilly lawsuit in 2026 refers to two major active federal MDLs: an antitrust class action over insulin pricing (MDL No. 2724, D.N.J.) and a product liability mass tort over GLP-1 drug injuries including gastroparesis (MDL No. 3094, E.D. Pa.).

A third track involves legacy Zyprexa claims, but that litigation is largely resolved and new filings face statute of limitations barriers in most states.

Who qualifies to file an Eli Lilly lawsuit?

Qualification depends on which track applies.

For the GLP-1 mass tort, the core requirements are documented use of Mounjaro, Zepbound, or Trulicity and a diagnosed serious GI injury such as gastroparesis.

For the insulin pricing class action, uninsured and underinsured consumers who paid out-of-pocket for Humalog or Basaglar at inflated prices during the class period are the primary qualifying class members.

How much is the Eli Lilly lawsuit settlement worth?

No global settlement has been finalized in either active MDL as of early 2026.

GLP-1 injury claimants with severe gastroparesis are projected to recover between $75,000 and $150,000+ per claim based on comparable mass tort benchmarks, with Tier 2 injuries in the $35,000 to $75,000 range.

The insulin antitrust class damages model estimates aggregate consumer overcharges exceeding $6.5 billion, though any eventual class settlement would represent a fraction of that theoretical maximum.

What is the filing deadline for an Eli Lilly lawsuit?

No court-ordered filing deadline has been issued in either MDL No. 2724 or MDL No. 3094 as of early 2026.

The operative deadline for each individual plaintiff is the statute of limitations under their state's law, typically 2 years from the date of injury discovery for product liability claims.

Missing the state statute of limitations bars the claim entirely, regardless of the MDL's administrative posture.

Which court is handling the Eli Lilly MDL?

The insulin pricing MDL (No. 2724) is before Judge Brian R. Martinotti in the U.S. District Court for the District of New Jersey, docketed as 2:17-md-02724.

The GLP-1 mass tort MDL (No. 3094) is before Judge Karen Marston in the U.S. District Court for the Eastern District of Pennsylvania, docketed as 2:23-md-03094.

Complaints must be filed in the correct court under the correct MDL structure to avoid administrative delays or improper venue issues.

Can I still join the Eli Lilly class action if I already stopped taking the medication?

Yes, for the insulin antitrust class action (MDL 2724), past use qualifies; the class period covers purchases made years ago.

For the GLP-1 mass tort, a plaintiff who discontinued Mounjaro or Trulicity but developed gastroparesis during or after use may still file an individual complaint, provided the state statute of limitations has not expired.

A plaintiff's attorney can assess whether the discovery rule extends the filing window based on when the injury was formally diagnosed.

Closing

The Eli Lilly lawsuit landscape in 2026 presents two active federal MDLs with real procedural milestones approaching. The GLP-1 bellwether trials scheduled for mid-2026 will generate the first jury-tested damages data for thousands of pending gastroparesis claims. The insulin MDL mediation is ongoing and may produce a settlement announcement at any point.

Patients who used Mounjaro, Zepbound, Trulicity, Humalog, or Basaglar and experienced documented serious harm should consult a plaintiff's attorney who specifically handles pharmaceutical mass torts or antitrust class actions. The statute of limitations runs on its own schedule regardless of MDL developments.

The cost of waiting is a permanently extinguished claim. The time to evaluate legal options is before that deadline passes.

Another useful guide: Shein Lawsuit 2026: Claims, Status and Who Qualifies